TY - JOUR
T1 - Impact of HLA Epitope Matching on Outcomes in Haploidentical HSCT With Distinct GVHD Prophylaxes
AU - Iwasaki, Makoto
AU - Kanda, Junya
AU - Tanaka, Hidenori
AU - Ikegame, Kazuhiro
AU - Shindo, Takero
AU - Kawase, Takakazu
AU - Yoshihara, Satoshi
AU - Doki, Noriko
AU - Nakamae, Hirohisa
AU - Eto, Tetsuya
AU - Tanaka, Takashi
AU - Ara, Takahide
AU - Hiramoto, Nobuhiro
AU - Kondo, Yukio
AU - Matsuoka, Ken Ichi
AU - Ando, Toshihiko
AU - Shono, Katsuhiro
AU - Nagafuji, Koji
AU - Fukuda, Takahiro
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Murata, Makoto
AU - Morishima, Satoko
N1 - Publisher Copyright:
© 2025 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2025/7/1
Y1 - 2025/7/1
N2 - Background. The introduction of posttransplant cyclophosphamide (PTCy) for prophylaxis against graft-versus-host disease (GVHD) has led to an increase in the number of transplants from haploidentical donors. Accordingly, we aimed to understand the impact of HLA epitope mismatch on the outcomes of haploidentical hematopoietic stem cell transplantation (HSCT) with prophylaxis against GVHD. Methods. This retrospective study included 1037 patients who underwent their first HSCT for hematologic malignancies from haploidentical peripheral blood donors in a Japanese registry between 2011 and 2019. In total, 542 patients received PTCy and 495 received antithymocyte globulin-based GVHD prophylaxis. Results. In patients with high-risk disease who received PTCy, higher class I Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE-I) scores were associated with a significantly lower risk of relapse, leading to a higher overall survival (OS: high PIRCHE-I patients compared with low PIRCHE-I patients: relapse: hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.46-0.98; P=0.040; mortality: HR, 0.69; 95% CI, 0.46-0.99; P=0.042). In patients with standard-risk disease who received antithymocyte globulin, a significant association between class II PIRCHE (PIRCHE-II) and a lower incidence of nonrelapse mortality (NRM) leading to higher OS was observed (high PIRCHE-II patients compared with low PIRCHE-II patients, NRM: HR, 0.41; 95% CI, 0.19-0.86; P=0.019; OS: HR, 0.55; 95% CI, 0.32-0.94; P=0.030). Conclusions. These findings suggest the differential effects of T-cell epitope matching based on GVHD prophylaxis after haploidentical HSCT. Pretransplant disease status may also be important for understanding the graft-versus-leukemia effect of mismatched HLA in haploidentical HSCT using PTCy.
AB - Background. The introduction of posttransplant cyclophosphamide (PTCy) for prophylaxis against graft-versus-host disease (GVHD) has led to an increase in the number of transplants from haploidentical donors. Accordingly, we aimed to understand the impact of HLA epitope mismatch on the outcomes of haploidentical hematopoietic stem cell transplantation (HSCT) with prophylaxis against GVHD. Methods. This retrospective study included 1037 patients who underwent their first HSCT for hematologic malignancies from haploidentical peripheral blood donors in a Japanese registry between 2011 and 2019. In total, 542 patients received PTCy and 495 received antithymocyte globulin-based GVHD prophylaxis. Results. In patients with high-risk disease who received PTCy, higher class I Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE-I) scores were associated with a significantly lower risk of relapse, leading to a higher overall survival (OS: high PIRCHE-I patients compared with low PIRCHE-I patients: relapse: hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.46-0.98; P=0.040; mortality: HR, 0.69; 95% CI, 0.46-0.99; P=0.042). In patients with standard-risk disease who received antithymocyte globulin, a significant association between class II PIRCHE (PIRCHE-II) and a lower incidence of nonrelapse mortality (NRM) leading to higher OS was observed (high PIRCHE-II patients compared with low PIRCHE-II patients, NRM: HR, 0.41; 95% CI, 0.19-0.86; P=0.019; OS: HR, 0.55; 95% CI, 0.32-0.94; P=0.030). Conclusions. These findings suggest the differential effects of T-cell epitope matching based on GVHD prophylaxis after haploidentical HSCT. Pretransplant disease status may also be important for understanding the graft-versus-leukemia effect of mismatched HLA in haploidentical HSCT using PTCy.
UR - https://www.scopus.com/pages/publications/85219679824
UR - https://www.scopus.com/pages/publications/85219679824#tab=citedBy
U2 - 10.1097/TP.0000000000005347
DO - 10.1097/TP.0000000000005347
M3 - Article
C2 - 39948727
AN - SCOPUS:85219679824
SN - 0041-1337
VL - 109
SP - 1241
EP - 1250
JO - Transplantation
JF - Transplantation
IS - 7
ER -